Peptide receptor radionuclide therapy: an overview.

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Peptide receptor radionuclide therapy (PRRT) targets cancer cells overexpressing specific receptors using radiolabeled peptides.
• PRRT offers high sensitivity and specificity for molecular-level cancer treatment.
• Advances in molecular biology are driving innovation and new possibilities in PRRT.

Purpose of the Study:

• To review current peptides and analogs used in PRRT.
• To discuss the applications and potential of these peptides in radionuclide therapy.
• To explore the role of peptide design, chelating agents, and radionuclide production in advancing PRRT.

Main Methods:

• Review of existing literature on PRRT peptides and analogs.
• Discussion of advancements in peptide library design and screening.
• Analysis of bifunctional chelating agents for radiolabeling.
• Examination of therapeutic radionuclide production for PRRT.

Main Results:

• Somatostatin analogs have been pivotal in PRRT for neuroendocrine tumors.
• Numerous peptides targeting various receptors show promise for PRRT breakthroughs.
• Combinatorial peptide libraries and chelating agents enhance peptide design and radiolabeling.
• Availability of therapeutic radionuclides is crucial for PRRT implementation.

Conclusions:

• PRRT is a rapidly evolving field with significant potential for targeted cancer therapy.
• Future PRRT applications may be tailored for patient-specific treatments.
• Continued advancements in peptide development and radionuclide availability are essential for expanding PRRT's scope.